Multiple stimuli-responsive nanosystem for potent, ROS-amplifying, chemo-sonodynamic antitumor therapy

Area of Science:

• Nanomedicine
• Oncology
• Biomedical Engineering

Background:

• Sonodynamic therapy (SDT) shows promise for non-invasive tumor treatment but is hindered by the hypoxic tumor microenvironment.
• Hypoxia limits SDT efficacy by reducing oxygen-dependent reactive oxygen species (ROS) generation.
• Novel strategies are needed to enhance SDT effectiveness in hypoxic tumors.

Purpose of the Study:

• To develop an oxygen-independent, ROS-amplifying chemo-sonodynamic therapy.
• To create novel pH/GSH/ROS triple-responsive nanoparticles for targeted drug delivery and enhanced antitumor effects.
• To investigate the therapeutic efficacy and biosafety of the developed nanoparticles.

Main Methods:

• Design and synthesis of PEG-PPMDT nanoparticles loaded with artemether (ART) and Fe3O4.
• Evaluation of nanoparticle drug release under acidic pH, high GSH, and ROS conditions.
• Assessment of chemo-sonodynamic therapy efficacy in human hepatocellular carcinoma (HepG2) xenografts in nude mice.
• In vivo MRI tracking using Fe3O4 as a contrast agent.
• Biosafety evaluation of the nanoparticles in major organs.

Main Results:

• ART/Fe3O4-loaded PEG-PPMDT nanoparticles demonstrated rapid drug release under simulated tumor conditions.
• The nanoparticles amplified ROS generation, independent of the hypoxic tumor microenvironment.
• Chemo-sonodynamic therapy resulted in significant tumor shrinkage, with 40% complete elimination of HepG2 xenografts.
• Fe3O4 enabled MRI guidance for therapeutic procedures.
• Minimal toxicity was observed in major organs, indicating good biosafety.

Conclusions:

• The developed triple-responsive nanoparticles offer a potent oxygen-independent chemo-sonodynamic therapy strategy.
• This approach effectively overcomes tumor hypoxia by amplifying ROS generation and accelerating drug release.
• The combination therapy shows significant antitumor efficacy and potential for guided treatment with MRI capabilities.